Plasma Total Nitric Oxide and Endothelial Constitutive Nitric Oxide Synthase (ecNOS) Inron 4 Gene Polymorphism: A Study in Children with Chronic Kidney Disease by Elshamaa, Manal F. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Plasma Total Nitric Oxide and Endothelial 
Constitutive Nitric Oxide Synthase (ecNOS) 
Inron 4 Gene Polymorphism: A Study in 
Children with Chronic Kidney Disease 
Manal F. Elshamaa1, Samar Sabry2, Ahmed Badr2, Eman A. Elghoroury3,  
 Soulaf Kamel3 and Gamila Elsaied4 
1Pediatric Department, National Research Centre,  
2Pediatric Department, Faculty of Medicine, Cairo University,  
3Clinical & Chemical Pathology Department, National Research Centre,  
 4Medical Biochemistry Department, National Research Centre,  
Egypt 
1. Introduction 
Considerable progress has been made in the treatment of end-stage renal disease over the 
past 20 yr. Nonetheless, the dialysis population continues to carry an excess mortality from 
fatal cardiovascular events [Baylis et al., 2006]. One possible explanation derives from the 
association of uremia and accelerated atherosclerosis [Tripathi et al., 2008]. The latter may be 
related to pre-dialysis factors such as preceding arterial hypertension, glucose intolerance, 
secondary hyperparathyroidism, dyslipidemia, and others. However, dialysis itself may 
further contribute to atherosclerosis by oxidative stress, cytokine stimulation, and other 
events inherent to hemodialysis (HD). Endothelial dysfunction has been shown recently to 
be a major initiating factor in atherosclerosis [Kone et al., 1997]. Endothelial dysfunction is 
associated primarily with decreased nitric oxide (NO). However, endothelial dysfunction of 
uremia has received little attention. 
Among the various factors involved in the deterioration of renal function, changes in the 
hemodynamic are thought to be important. Nitric oxide (NO), an important endothelium 
derived relaxing factor, is synthesized in the vascular endothelium by the NO synthase. NO 
is a potent regulator of intrarenal hemodynamics [Baylis et al., 2006 and Tolins et al., 1990]. 
At the release site it mediates local vasodilatation, antagonizes platelet aggregation, inhibits 
vascular smooth muscle cell proliferation and also, regulates some vessel-platelet 
interactions, limits the oxidation of atherogenic low density lipoproteins and has a 
vasoprotective effect by scavenging superoxide radicals and suppresses leukocyte adhesion 
to endothelial vessel wall. Multiple lines of evidence have suggested that NO plays a 
protective role in various important events during atherogenesis. Reduced NO levels are 
involved in the pathogenesis of the vascular endothelium due to the loss of its vasodilatory 
effect [Schmidt et al., 1994]. In the kidney, NO dilates renal blood vessels and modulates 
renin secretion [Kone et al., 1997 and Tripathi et al., 2008]. An impairment of NO production 
www.intechopen.com
 
Hemodialysis - Different Aspects 
 
18
causes abnormalities in vascular function in many diseases including human arterial 
hypertension and renal disease [Schmidt et al., 2000 and Tang et al., 2008].  
The endothelial constitutive NO synthase (ecNOS), which produces NO from L-arginine, is 
encoded by a gene located on chromosome 7q35-36, expressed in endothelium [Baylis et al., 
2006 and Nadaud et al., 1994]. Recently, several studies have shown that the polymorphisms 
of ecNOS are related to the haemodynamics. There are two alleles identified in intron 4 of 
the ecNOS gene. The larger allele, 4b, consists of five tandem 27-bp repeats and the smaller 
one, 4a, has four repeats [Wang el al., 1999 and Yilmaz et al., 2009]. 
Several allelic variants of eNOS gene have been identified and their association with human 
diseases states has been studied. The evidence suggests that NO may inhibit several key 
steps in the atherosclerosis process and that an alteration in NO production within the 
vascular endothelium could contribute to pathogenesis of atherosclerosis. Several eNOS 
gene polymorphisms have been reported as “susceptibility genes” in various cardiovascular 
(CVD) and pulmonary diseases. GT substitution in exon7 in codon 298, T786 mutation in the 
5´ flanking region and high numbers of CVD , which have been repeated in intron 13 of 
eNOS gene are also known to be associated with an excess of risk of coronary artery disease 
(CAD) [Asakimori et al., 2001]. Among the reported polymorphisms of the eNOS gene, a 
significant association of the 4a/b polymorphism in intron 4 of the eNOS gene with CAD 
and arterial hypertension has also been reported (Yoon et al.2000). 
Ichihara et al., in 1998 observed an association between the ecNOS4a allele and myocardial 
infarction in both a smoking and non-smoking Japanese population. As both coronary 
lesions and chronic renal failure are basically vascular disorders, we speculate that the gene 
polymorphism in ecNOS intron 4 might have some relevance to progression in chronic renal 
failure. 
An association of the 4a allele of the ecNOS gene with renal disease was reported [Asakimori 
et al., 2001, Miyamotoet al., 1998 and Thaha et al., 2008]. Chronic renal failure is basically a 
vascular disorder and investigating ecNOS gene polymorphism might shed some light on 
the pathophysiology of renal disease and progression to end-stage renal disease (ESRD).  
2. Aim of work 
We investigated (a) the relevance of the ecNOS   intron 4 polymorphism to the development 
and progression of chronic renal failure, (b) its relationship with arterial hypertension and 
cardiovascular complications in CKD pediatric patients undergoing maintenance 
hemodialysis (MHD) or conservative treatment (CT). 
3. Subjects and methods 
Seventy eight Egyptian pediatric patients with advanced CKD [stages 4 and 5 based on 
estimated glomerular filtration rate (eGFR) according to the National Kidney Foundation 
classification [National Kidney Foundation, 2002], were included in the study (Table 1). 
They were divided into two groups undergoing CT (n=32) or MHD (n=46). MHD children 
were selected from the hemodialysis Unit of the Center of Pediatric Nephrology and 
Transplantation (CPNT), while CT children were selected from the Nephrology Pediatric 
Clinic, Children’s Hospital, Cairo University. The study was done from April 2009 to 
December 2009.  
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Stage Description 
GFR  
(mL/min. per 1.73 m2)
Related terms 
1 
 
Kidney damage with  
normal or ↑ GFR ≥ 90 
Albuminuria 
Proteinuria 
Haematuria 
2 
 
Kidney damage 
with mild ↓ GFR 60–89 
Albuminuria 
Proteinuria 
Haematuria 
3 Moderate ↓ GFR 30–59 
CKD 
Early renal 
insufficiency 
4 Severe ↓ GFR 15–29 
CKD 
Late renal 
insufficiency 
Pre-ESRD 
5 Kidney failure 5 <15 
Renal failure 
Uraemia 
End-stage 
renal disease 
Table 1. Classification of chronic kidney disease (National Kidney Foundation, 2002) 
In CT patients the causes of renal failure were renal hypoplasia or dysplasia (n=14), 
obstructive uropathies (n=8), neurogenic bladder (n=4), not known (n=4), or metabolic 
(n=2). In MHD, the causes of renal failure were hereditary nephropathies (n=17), obstructive 
uropathies (n=6), neurogenic bladder (n=2), glomerulopathy (n=2), renal hypoplasia or 
dysplasia (n=2), and unknown causes (n =17).The inclusion criteria for MHD patients 
included patients with onset of HD below 16 years with at least 6 months duration on MHD. 
They were treated with hemodialysis for 3–4 h three times weekly with a polysulfone 
membrane using bicarbonate-buffered dialysate. The duration of hemodialysis was 2.75 
±1.59 years. Measurement of HD adequacy was as follows: the delivered dose of HD was 
described as the fractional clearance of urea as a function of its distribution volume (Kt/V) 
and was determined by using the Kt/V natural logarithm formula according to the equation  
 ( ) ( )Kt / V  Ln R 0.008 xt   4 3.5 R  UF /W= − + −  (1) 
Where Ln= natural logarithm, R = post-dialysis BUN/ pre-dialysis BUN. t=dialysis session 
length in hours, UF= ultrafiltration volumes in liters. W=patients post-dialysis weight in 
kilogram. 
Thirty two MHD patients and 16 CT patients were taking antihypertensive treatment. The 
following classes of drugs were employed: α-adrenoceptor antagonists in two MHD and two 
CT, ß-blockers in nine MHD, ACE inhibitors in seventeen MHD, and  six CT patients and Ca 
channel blockers in twenty-nine MHD and ten CT patients. Subjects were taking their 
medication when ACE activity was measured and no influence of medication on the 
measurement. 
All control subjects (n=30) were healthy with no clinical signs of vascular or renal disease 
and no family history of renal disease, as well as lack of medications taken at the time of the 
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study. Control subjects were selected to be matched for age and gender to the patient 
groups, as well as within the same BMI limits. They were collected from the pediatric clinic 
of National Research Centre (NRC), Cairo, Egypt. An informed consent for genetic studies 
was obtained from parents of all participants. The protocol of the study was read and 
approved by the Ethics Committee of NRC in Egypt. 
3.1 Diagnostic criteria of vascular disease 
We studied the prevalence of vascular disease in children with CKD according to the 
following criteria [Kimura et al. 1999]. 
Cardiac disease: the presence of primary dilated cardiomyopathy previously diagnosed 
clinically and by echocardiography. 
Cerebral vascular disease: cerebral vascular disease was suspected on clinical grounds, i.e., 
rapidly developing signs of focal disturbance of cerebral function such as hemiparesis and 
hemisensory impairment. The diagnosis was confirmed by computed tomography or 
magnetic resonance imaging. Brain hemorrhage and subarachnoid hemorrhage were 
excluded. 
A patient was considered to have a vascular disease when at least one of these two defined 
vascular disease was present. 
3.2 Biochemical markers 
Venous blood samples were collected in the morning after an overnight fast on a midweek 
dialysis day, before the dialysis session. Three ml of venous blood sample was collected in 
EDTA vials for the extraction of genomic DNA. Complete blood count and pre- and post-
dialysis kidney function test were determined by standard laboratory methods. Estimations 
of the plasma concentration of total cholesterol (TC), triglyceride (TG) and HDL cholesterol 
were made by using an Olympus AU400 (Olympus America, Inc., Center Valley, Pa., USA). 
3.3 Quantitative determination of nitric oxide concentration in serum 
It is done by using the Griss reaction after ultrafiltration via the immunosorbent assay (R&D 
system. Inc. Minneapolis, MN55413, USA) [Tsikas, 2005] . 
3.4 Determination of ecNOS genotype  
DNA was extracted from peripheral blood using a QIAamp Blood miniprep extraction Kit 
(QIAGEN, Germany) and was stored at 4oC until analysis. eNOS genotypes were 
determined by the polymerase chain reaction (PCR). Briefly, the oligonucleotide primers 
(the forward primer sequence was 5′-AGGCCCTATGGTAGTGCCTTT -3′ which was 
located at position 5111-5130 base pairs of the genomic sequence of NOS, and the sequence 
of the reverse primer was 5′-TCTCTTAGTGCTGT GGTCAC-3′ which its position within the 
genomic sequence of NOS was 5530-5511 bp) that flank the region of the 27-bp direct repeat 
in eNOS intron 4 were used for DNA amplification [Salimi et al., 2006]. Each reaction 
mixture was heated to 94°C for 4 min for denaturation and underwent 35 cycles at 94°C for 
one min, annealing at 56°C for one min with an extension at 72°C for two min, and a final 
extension at 74°C for seven min. The PCR products were analysed by 2% agarose gel 
electrophoresis and fragments were visualized by ethidium bromide staining and ultraviolet 
transillumination [Figure 1]. 
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Lanes (2,3,5&7) show a single band at 420bp representing the homozygous allele B pattern (NOSB/B). 
Lanes (4&8) represent the heterozygous pattern for allele A and allele B (NOSA/B).  
Lane (6) shows one band at 393bp representing the homozygous allele A pattern (NOSA/A).  
Lane 1 denotes molecular weight ladder marker 100-1000bp (Sigma, St. Louis, USA). 
Fig. 1. Genotyping of NOS polymorphism photographed on a 2% agarose gel 
electrophoresis resolving the wild type allel B at 420bp and the polymorphic allele A at 
393bp. 
3.5 Statistical analysis  
Statistical package for social science (SPSS) program version 11.0 was used for analysis of 
data. Data were summarized as mean ± SD, range or percentage. Histograms and normality 
plots were used for evaluating the normality of data. For those data with abnormal 
distribution, log transformation was performed before a t-test. The number of subjects 
required for each subgroup was determined by survey sampling basics: Analytical Plan, 
Population Variability & Confidence Intervals. Data were valuated between the 
experimental groups by One-Way Analysis of Variance (ANOVA) followed by Tukey's 
multiple comparison test. Allele and genotypic frequencies for ecNOS alleles were 
calculated with the gene counting method. Hardy–Weinberg equilibrium was tested with 
the X2 test. Comparison of the categorical data i.e. different ecNOS genotypes among 
patients was done by independent-samples t test where appropriate after evaluating the 
normality of data. Fisher's exact test and X2 test were done to confirm the results. . Multiple 
regression analysis was performed to assess the influence of ecNOS alleles on hypertension 
and vascular diseases. A p value of < 0.05 was considered significant.  
4. Results 
Clinical and biochemical characteristics of the studied groups were summarized in Table 
2. There were no significant differences between groups with respect to age, gender ratio 
and total serum cholesterol level.  Serum NO level was significantly higher in both MHD 
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and CT groups than the controls and the level was significantly higher in MHD group 
than CT group (143.93±35.99 µmol/L, 91.48±28.80µmol/L, 51.84±12.39 µmol/L, 
respectively). 
The distribution of genotypes and allele frequencies were compared between patients and 
controls (Table 3). The genotype frequencies were in agreement with Hardy–Weinberg 
equilibrium. The Hardy-Weinberg equation is in the following form 
 2 22     1p p q q+ + =  (2) 
Where p is the frequency of the A allele in the population and q is the frequency of the a 
allele in the population.  
The frequencies of genotypes in the population are given by  
• p2 for genotype AA,  
• 2pq for genotype Aa,  
• q2 for genotype aa. 
Dialyzed and CT patients had significantly higher frequency of the aa genotype and 
ecNOS4a allele (P<0.05) compared with control subjects. The multiple logistic regression 
analysis with correction for age and sex revealed that the frequency of the ecNOS4a allele 
carriers was significantly higher in dialysed and CT patients than in healthy subjects. There 
was no significant difference between MHD and CT groups as regard to aa genotype 
(p>0.05). 
Comparing clinical and biochemical characteristics of carriers of the ecNOS 4a allele (aa+ ab 
genotypes) and non carriers (bb genotype) were shown in Table 4. Hypertensive % was 
found to be higher in carriers of the ecNOS 4a allele than in non carriers - bb genotype - 
(85.95%vs 60.67%, p=0.04). Also, cardiovascular % was significantly higher in carriers of the 
ecNOS 4a allele than in non carriers - bb genotype-, ( 35.90%vs 5.13%, p=0.01). There were 
significant differences between the two subgroups as regard to triglycerides and HDL 
cholesterol (190.00±57.15 mg/dL vs 116.25±48.49 mg/dL, p=0.02 and 21.22±7.05 mg/dlL vs 
32.00±15.96 mg/dL, p=0.03, respectively). Serum NO level was found to be lower in carriers 
of the ecNOS 4a allele than in non carriers (100.29±27.32 (µmol/L) vs 152.73±60.39 (µmol/L), 
p=0.04). 
To examine the survival bias in evaluating the effect of the ecNOS4 polymorphism on renal 
disease, we analyzed allele and genotype frequencies in MHD subjects shorter than 3 years 
on dialysis and those dialyzed 3 years or longer (data not shown). There were no statistically 
significant differences between these two groups (p=NS), suggesting little or no influence of 
survival bias on the outcome of the study. 
We performed a multiple linear regression analysis with backward stepwise selection using 
all the clinical risk factors for hypertension and the mutant allele of the eNOS 4 a gene. This 
analysis revealed that the most predictive independent risk factors for hypertension were 
the mutant allele (ß=0.50, p=0.03), NO level (ß =-0.47, p=0.03) and TG (ß=0.60, p=0.02) in 
Table 5. 
A multiple linear regression analysis using a model identical to the one used to test 
hypertension was used to test vascular disease for the relationship with the mutant allele of 
the eNOS 4 a gene. This analysis suggested that the allele has a dominant effect on the risk 
of vascular complications in these children (ß =0.99, p=0.04) in Table 6. 
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CT 
(n=32) 
MHD 
(n=46) 
Controls 
(n=30) 
Age 9.14±7.59 10.62±3.49 8.7±4.51 
Gender (M/F) 
15 
(46.88%)/17(53.12%) 
25(54.35%)/21(45.65%) 20(66.67%)/10(33.33%) 
SBP (mmHg) 98.66±6.66 127.13±18.37 b* 94.55±9.80 
DBP (mmHg) 64.66±6.67 85.15±13.76 b* 60.59±10.11 
Creatinine 
(mgdL) 
3.93±3.75 a* 6.32±1.55 b* 0.77±0.34 
Predialysis 
urea (mg/dL) 
51.12±10.45 a* 71.56±20.61 b* 7.80±2.64 
Dialysis, Yrs  2.75±1.59  
Kt/V  1.69±0.42  
Total 
cholesterol 
(mg/dL) 
164.44±50.10 193.04±51.37 b* 160.31±18.74 
Triglycerides 
(mg/dL) 
160.78±57.33 a** 147.00±66.98 b** 65.31±18.35 
HDL 
cholesterol 
(mg/dL) 
21.35±1.17a* 27.34±9.88 b* 39.55±7.94 
Serum NO 
level (µmol/L) 
91.48±28.80a* 143.93±35.99b**c 51.84±12.39 
 
Data was evaluated by ANOVA test. Values are presented as means ±SD or percentage as applicable. 
CT=conservative treatment, MHD=maintenance hemodialysis, SBP=systolic blood pressure, 
DBP=diastolic blood pressure, Kt/V=adequacy of hemodialysis, a*P<0.05 or a**P<0.01 vs controls and 
CT b*P<0.05 or b**P<0.01 vs control and MHD, cP<0.01 vs CT and MHD. 
Table 2. Clinical and biochemical data of the studied groups 
 
 
Gene 
CT 
(n=32) 
MHD 
(n=46) 
Controls 
(n=30) 
 
Alleles 
b 43(67.19%) 61(66.30%) 47(78.33%) 
a 21(32.81%) 31(33.70%) b 13(22.67%) 
Genotypes 
bb 16(50%) 23(50.00 %) 17(56.67%) 
ab 11(34.38%) 15(32.61%) 13(43.33%) 
aa 5(15.62%) a 8(17.39%) b 0(0.00%) 
 
Data was evaluated by the gene counting method. Values are presented as percentage. CT=conservative 
treatment, MHD=maintenance hemodialysis.  
ap<0.05 vs control and CT 
bp<0.05 vs control and MHD 
Table 3. Frequencies of ecNOS intron 4 genotypes in patients and controls 
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aa + ab 
(n=39) 
bb 
(n=39) 
P value 
Age 11.66±4.77 9.33±3.25 NS 
SBP(mmHg) 120.25±22.47 114.00±15.95 NS 
DBP(mmHg) 79.37±13.40 77.47±13.80 NS 
Hypertensive% 85.95% 60.67% 0.04* 
Cardiovascular disease% 14(35.90%) 2(5.13%) 0.01* 
Total cholesterol(mg/dl) 183.00±38.96 180.00±68.67 NS 
Triglycerides(mg/dl) 190.00±57.15 116.25±48.49 0.02* 
HDL-cholesterol( mg/dl) 21.22±7.05 32.00±15.96 0.03* 
Creatinine( mg/dl) 5.99±2.06 5.44±2.15 NS 
Predialysis urea(mg/dl) 69.88±27.84 67.00±23.01 NS 
Serum NO level (µmol/l) 100.29±27.32 152.73±60.39 0.04* 
 
Significance was estimated using independent t-test. Data are means ± SD. SBP=systolic blood pressure, 
DBP=diastolic blood pressure, NO=nitric oxide, p is significant if <0.05, NS=non significant. 
Table 4. Clinical characteristics of CKD patients with different ecNOS intron 4 genotypes 
 
 
 ß P value 
Age 0.06 NS 
Triglycerides(mg/dl) 0.60 0.02* 
Serum NO level (µmol/l) 0.47 0.03* 
Mutant allele (a allele) 0.50 0.03* 
 
NO= nitric oxide, P<0.05 was considered significant  
Table 5. Risk factors affecting hypertension in CKD patients based on multiple linear 
regression analysis 
 
 
 ß P value 
Age 0.07 NS 
Hypertension% 0. 60 0.02* 
SBP 2.19 0.03* 
DBP 2.60 0.02* 
Serum NO level (µmol/l) 0.41 0.03* 
Mutant allele (a allele) 0.99 0.04* 
 
SBP=systolic blood pressure, DBP=diastolic blood pressure, NO= nitric oxide, p<0.05 was considered 
significant. 
Table 6. Risk factors affecting cardiovascular disease in CKD patients based on multiple 
linear regression analysis.  
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5. Discussion 
Chronic renal failure is a multifactorial disease with different prevalence and clinical 
phenotype in different populations. This study is an attempt to describe the functional state 
of the NO system in patients on chronic HD, using carefully matched control subjects.  
More than 99% of human DNA sequences are the same across the population, however, 
variations in DNA sequence can have a major impact on how humans respond to 
environmental insults such as toxins. The single nucleotide polymorphisms (SNPs) or snips 
are DNA sequence variations that occur when a single nucleotide in the genome sequence is 
altered. A point mutation is considered as SNP if it occurs in at least in 1% of the population. 
The SNPs are responsible for about 90% of all human genetic variation and occur every 100–
300 bases along the 3-billionbases of human genome both in coding and non-coding 
regions. Two-third of known SNPs involves the replacement of cytosine with thymine. The 
SNPs that have no effect on cell function could predispose people to disease or influence 
their response to a toxicant [Agarwal et al., 2003]. 
Gene and environment play a critical role in many genetic disorders of multi-factorial 
origin. Epidemiological studies have shown statistically significant association of several 
factors among which genetic susceptibility is the common factor as indicated by familial 
aggregation and greater concordance in monozygotic twins with the onset of the diseases 
such as obesity, cancer, hypertension, and diabetes [Agarwal et al.,2003]. The PCR- and 
sequencing-based techniques have been used to assess the presence of SNPs in a particular 
gene. Genome–environment interaction among individuals for the susceptibility to a disease 
greatly varies and Fosmid library allele-specific haplotypes analysis (FLASH) and large 
insert genome analysis (LIGA) has improved the understanding of genetic variations in 
various populations.[Kaul, 2003] FLASH allows to isolate and sequence fosmid clones that 
tile a given loci in a haplospecific manner over along genomic region of interest and LIGAN 
allows the use of end sequence and fingerprint data to identify the variant genomic regions 
from multiple individuals.[ Kaul, 2003] FLASH and LIGAN have overcome the limitations 
of PCR-based re-sequencing methods to screen thousands of individuals [Agarwal et al., 
2003] .FLASH does not provide phase information for the underlying haplotypes structure 
of a diploid genome and LIGAN provides a limited resolution at the chromosome 
level.[Kaul, 2003]. Telomeric repeat amplification protocol (TRAP), a sensitive, high 
throughput PCR-based assay provides a reliable tool for the experiments that requires 
massive quantitation of telomerase activity, however, a pyraseme diated allele-specific 
extension reaction (AMASE) is a novel tool used for microarray-based mutation detection 
and allows the simultaneous, efficient, and accurate analysis of several samples from 
different stages of skin malignancies [Kaller et al., 2004].  
In this study the frequency of a allele in the ecNOS  intron 4 was significantly higher in both 
dialyzed and CT patients compared with in healthy controls indicating that the ecNOS 4a 
allele is a risk factor for ESRD in children with CKD. Such an association was observed 
earlier by others. Asakimori et al, in 2001, found a significantly higher frequency of the 
ecNOS 4a allele in haemodialysis patients, both non-diabetic and diabetic, and therefore 
suggested that the polymorphism in intron 4 of the ecNOS gene may have influence on the 
progression of renal disease. Wang et al, in 1999, in their study of 302 subjects with end-
stage renal disease and 248 healthy controls found a significantly higher frequency of the 
ecNOS 4a allele in patients with ESRD caused by non-diabetic primary renal diseases. 
Freedman et al.2000 evaluated the role of four NOS gene polymorphisms in ESRD patients 
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and found that the a allele of the ecNOS 4 polymorphism in the NOS gene was associated 
with all-cause ESRD in probands and their siblings compared with healthy subjects.  
One study showed that the basal concentration of NO metabolites (nitrate plus nitrite) in the 
plasma was reduced in individuals with essential hypertension [Asakimori et al., 2001 and 
Yilmaz et al., 2009]. Tsukada et al.,1998  reported a strong association between the a allele of 
the ecNOS gene and the plasma NOx (nitrate and nitrite) levels.  
In our study, there was a significant elevation of serum NO levels in patients with CKD 
either on MHD or on CT than the controls and the level was significantly higher in MHD 
group than CT group. Nitric oxide, an extensively studied endothelium relaxing factor, is 
reported to be a very potent regulator of intrarenal hemodynamics [Kerkeni et al., 2009 and 
Möllsten et al., 2009] . It plays a major role in the regulation of cardiovascular homeostasis 
both in health and disease. Many studies have published the relation between NO and renal 
failure. An impaired response to NO may contribute to the initiation or maintenance of the 
increased intra-glomerular high pressure state. The impaired response to NO appeared 
more in MHD patients as they are to exposed to increased oxidative stress and this may 
explain the higher level in this group [Nguyen-Khoa et al., 2001]. 
In the present study, serum NO level was found to be lower in carriers of the ecNOS 4a 
allele than in non carriers. Gururajan et al., (2010) reported a strong association between the 
a allele of the ecNOS gene and the plasma NOx (nitrite and nitrate) levels. The mean plasma 
level of NOx of the subjects who were homozygous for a allele was nearly 20% lower than in 
the subjects with the b allele. Although it is disputable whether the NO metabolites in the 
blood are derived entirely from ecNOS in the endothelial cells of the blood vessels, it is in 
fact that plasma NO levels are different depending on ecNOS gene polymorphism. They 
concluded therefore that the ecNOS gene locus might be responsible for variations in the 
genetic control of plasma NOx. Failure of vascular endothelium to elicit NO-mediated 
vasodilation may be due to decreased formation, increased degradation, decreased 
sensitivity to nitric oxide formed, or a mixture of these factors. Decreased levels of nitric 
oxide may also be due to the increased activity of the enzyme myeloperoxidase, which 
consumes nitric oxide as a substrate and also promotes endothelial dysfunction. 
The molecular mechanism by which ecNOS gene polymorphism acts to affect the 
occurrence of ESRD is not known, and it is also unclear whether this polymorphism is a 
causative variant or a marker of another functional variant. However, the fact that the 
distribution of a allele in the ecNOS intron 4 showing a significantly higher incidence in 
children with CKD and plasma NO metabolite levels are reported to be different in 
depending on ecNOS gene polymorphism, suggests that the ecNOS intron 4 is a useful 
marker for studying the relationship between NO and the progression of renal disease.  
The subjects of the MHD group have been dialyzed for relatively long periods. Therefore we 
examined the survival bias. The frequencies of ecNOS intron 4gene polymorphism in the 
long dialysis period group did not differ from those in the short period group. It appears 
therefore, that neither death nor survival is factors in estimating the role of gene 
polymorphism in disease progression. 
In this study, hypertensive % was found to be higher in carriers of the ecNOS 4a allele than 
in non carriers (bb genotype) and on correlating the diastolic blood pressure (DBP) to the a 
allele and other individual variables by multiple linear regression analysis, the a allele, NO 
level and TG concentration were variables that were independently associated with DBP 
(p<0.05). In a study using mice with disrupted eNOS gene revealed that eNOS function is 
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required for vascular and hemodynamic responses to acetylcholine and that the disruption 
of the eNOS gene leads to hypertension [Huang et al., 1995 and Tripathi et al. 2008]. Clinical 
and experimental studies suggest that an alteration in nitric oxide (NO) metabolism may be 
a contributing factor in the pathogenesis of hypertension. Thus, abnormalities in the activity 
of the enzyme endothelial NO synthase (eNOS) that synthesizes NO in endothelial cells may 
lead to NO abnormality with severe consequences.[Möllsten et al., 2009]. Inhibition of eNOS 
elevates blood pressure in healthy humans [Haynes et al., 1993]. Furthermore, NO 
production is diminished in patients with essential hypertension, under basal conditions 
[Forte et al., 1997 and Möllsten et al., 2009]. 
Our study revealed that the cardiovascular disease % was significantly higher in carriers of 
the ecNOS 4a allele than in non carriers (bb genotype) and that the allele has a dominant 
effect on the risk of vascular complications in children with CKD by multiple linear 
regression analysis. Apart from controlling the coronary blood flow, there is now an 
emerging consensus that NO generally acts to fine-tune and optimize cardiac pump 
function [Cotton et al., 2002]. Excessive NO depresses systolic function by decreasing 
myocardial contractility and shortening the ejection period [Cotton et al., 2002]. Elevated 
circulating levels of oxidative products of (NOx) and myocardial NO synthetase expression 
have been seen in patients with heart failure due to contractile dysfunction [Balat et al., 2003 
and Kerkeni et al., 2009]. We had a previous study on the relation between plasma NO level 
and left ventricular diastolic function and its etiology in heart failure patients in the 
pediatric age group. We performed echocardiographic Doppler studies in 47 patients with 
congestive heart failure. Left ventricular diastolic dysfunction was classified as either a 
restrictive (RFP) or non restrictive filling pattern (non-RFP). Plasma NOx level was 
significantly higher in the studied patients than the control group. Plasma NOx levels are 
elevated in patients with isolated diastolic heart failure, in addition, in patients with LV 
systolic failure, the severity of LV diastolic dysfunction determines the amount of NO 
production [Elshamaa et al., 2006]. Many studies reported a correlation of this 
polymorphism with vascular diseases [Mitsuke et al., 2001, Thibaud  et al., 2004 and Wasson 
et al., 2004].  
The intron 4ab insertion/deletion genotype was associated with isolated lacunar infraction. 
Protective effect of the 4a variant could be mediated through changes in eNOS promoter 
activity and increased NO levels has been suggested through Haplotype and functional 
studies [Hoffmann et al., 2000]. Another study by Markus et al., 1998 of a Turkish 
population has shown that carriers of the minor ‘a’ allele of intron 4 VNTR had significantly 
elevated risk for stroke (a). An over representation of 4c allele of intron 4 VNTR in ischemic 
stroke patients was suggested in a study involving African American population. In pooled 
analysis of all patients, intron 4c, but not intron 4a, intron 4b, or 894G/T alleles are 
associated with stroke.  In subgroup analysis by race, the intron 4c allele is most strongly 
associated with large artery ischemic stroke in African Americans [Yemişçi et al., 2009]. The 
association of SNP in exon 7 with stroke was seen only in the study of Hoffmann et al., 2000, 
while other studies indicated negative finding in white population. Further more Hingorani 
et al. (1999) also measured carotid stiffness in stroke patients and found it was unrelated to 
the exon 7 variant. 
The limitation of this study includes the small sample size as we collected cases from one 
centre. Thus, a large number of patients and controls need to be examined to confirm the 
association of this polymorphism in the Egyptian pediatric population. 
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6. Conclusion   
A allele of the ecNOS intron 4 gene polymorphism showed a significantly higher frequency 
in children with CKD, both on MHD and CT. These results suggested that the ecNOS gene 
polymorphism could serve as a useful genetic marker for evaluation of susceptibility to 
chronic renal failure. Plasma NO levels showed a significant decrease in aa alleles patients 
and also could independently predict the risk. However, the interactions between this 
genetic predisposition and environmental factors as well haplotype analysis require further 
studies. A large number of patients and controls need to be examined to confirm the 
association of this polymorphism in the Egyptian pediatric population. 
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